VVOS
Income statement / Annual
Last year (2025), Vivos Therapeutics Inc's total revenue was $17.44 M,
an increase of 16.05% from the previous year.
In 2025, Vivos Therapeutics Inc's net income was -$21.23 M.
See Vivos Therapeutics Inc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
| Operating Revenue |
$17.44 M |
$15.03 M |
$13.80 M |
$16.02 M |
$16.89 M |
$13.07 M |
$11.39 M |
$3.79 M |
| Cost of Revenue |
$6.90 M
|
$6.01 M
|
$5.53 M
|
$6.01 M
|
$4.28 M
|
$2.65 M
|
$2.74 M
|
$1.08 M
|
| Gross Profit |
$10.54 M
|
$9.02 M
|
$8.27 M
|
$10.02 M
|
$12.60 M
|
$10.41 M
|
$8.66 M
|
$2.71 M
|
| Gross Profit Ratio |
0.6
|
0.6
|
0.6
|
0.63
|
0.75
|
0.8
|
0.76
|
0.71
|
| Research and Development Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| General & Administrative Expenses |
$27.73 M
|
$17.88 M
|
$22.48 M
|
$29.04 M
|
$25.79 M
|
$16.09 M
|
$16.17 M
|
$9.27 M
|
| Selling & Marketing Expenses |
$1.40 M
|
$1.73 M
|
$2.47 M
|
$5.34 M
|
$5.55 M
|
$2.31 M
|
$2.31 M
|
$1.16 M
|
| Selling, General & Administrative Expenses |
$29.13 M
|
$19.61 M
|
$24.95 M
|
$34.38 M
|
$31.34 M
|
$18.40 M
|
$18.48 M
|
$10.44 M
|
| Other Expenses |
$1.31 M
|
$581.00 K
|
$621.00 K
|
$669.00 K
|
$733.00 K
|
$4.05 M
|
$751.23 K
|
$610.67 K
|
| Operating Expenses |
$30.44 M
|
$20.19 M
|
$25.57 M
|
$35.05 M
|
$32.08 M
|
$22.45 M
|
$19.23 M
|
$11.05 M
|
| Cost And Expenses |
$37.34 M
|
$26.20 M
|
$31.10 M
|
$41.06 M
|
$36.36 M
|
$25.11 M
|
$21.97 M
|
$12.13 M
|
| Interest Income |
$0.00
|
$0.00
|
$0.00
|
$89.00 K
|
$117.00 K
|
$79.61 K
|
$21.13 K
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$14.00 K
|
$96.68 K
|
$137.88 K
|
$102.97 K
|
| Depreciation & Amortization |
$1.31 M
|
$581.00 K
|
$621.00 K
|
$669.00 K
|
$733.00 K
|
$718.00 K
|
$751.23 K
|
$610.67 K
|
| EBITDA |
-$19.92 M |
-$10.56 M |
-$12.96 M |
-$23.18 M |
-$19.54 M |
-$11.24 M |
-$9.87 M |
-$7.73 M |
| EBITDA Ratio |
-1.14
|
-0.7
|
-0.94
|
-1.45
|
-1.16
|
-0.86
|
-0.87
|
-2.04
|
| Operating Income Ratio |
-1.14
|
-0.74
|
-1.25
|
-1.56
|
-1.15
|
-0.92
|
-0.93
|
-2.2
|
| Total Other Income/Expenses Net |
-$1.34 M
|
$35.00 K
|
$3.71 M
|
$1.19 M
|
-$817.00 K
|
-$17.00 K
|
-$177.09 K
|
-$102.97 K
|
| Income Before Tax |
-$21.23 M
|
-$11.14 M
|
-$13.58 M
|
-$23.85 M
|
-$20.29 M
|
-$12.06 M
|
-$10.75 M
|
-$8.44 M
|
| Income Before Tax Ratio |
-1.22
|
-0.74
|
-0.98
|
-1.49
|
-1.2
|
-0.92
|
-0.94
|
-2.23
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$21.23 M
|
-$11.14 M
|
-$13.58 M
|
-$23.85 M
|
-$20.29 M
|
-$12.06 M
|
-$10.75 M
|
-$8.44 M
|
| Net Income Ratio |
-1.22
|
-0.74
|
-0.98
|
-1.49
|
-1.2
|
-0.92
|
-0.94
|
-2.23
|
| EPS |
-2.06 |
-2.22 |
-11.14 |
-25.9 |
-23.89 |
-24.7 |
-21.94 |
-18.49 |
| EPS Diluted |
-2.06 |
-2.22 |
-11.14 |
-25.9 |
-23.89 |
-24.7 |
-21.94 |
-18.49 |
| Weighted Average Shares Out |
$10.27 M
|
$5.02 M
|
$1.22 M
|
$920.48 K
|
$849.32 K
|
$728.38 K
|
$496.43 K
|
$461.93 K
|
| Weighted Average Shares Out Diluted |
$10.27 M
|
$5.02 M
|
$1.22 M
|
$920.48 K
|
$849.32 K
|
$728.38 K
|
$496.43 K
|
$461.93 K
|
| Link |
|
|
|
|
|
|
|
|
